DVL1 and colorectal carcinoma: Inhibitors that target the cholesterol–Dvl interaction effectively suppress β-catenin signaling and reduce viability in APC-truncated CRC cells.22 However, the role of APC mutations in mediating immune evasion remains poorly understood.